Key result
Telmisartan provides sustained blood pressure reduction and exhibits unique cardiovascular protective properties, including PPAR-γ modulation, that extend beyond its antihypertensive effects.
Telmisartan is an ARB with unique pharmacological properties, including PPAR-gamma modulation, that offer cardiovascular and end-organ protection beyond blood pressure control.
Answers are grounded in this paper and cite their sources.
Telmisartan's organ-protective signals beyond BP control merit targeted trials; leaves open any practice shift pending confirmatory RCTs.
INTRODUCTION: The modulation of the renin angiotensin aldosterone system (RAAS) is an important pathway in managing high blood pressure, and its overexpression plays a key role in target end-organ damage. Telmisartan is an angiotensin II receptor blocker (ARB) with unique pharmacologic properties, including the longest half-life among all ARBs; this leads to a significant and 24-h sustained reduction of blood pressure. Telmisartan has well-known antihypertensive properties, but there is also strong clinical evidence that it reduces left ventricular hypertrophy, arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection. AREAS COVERED: This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications. EXPERT OPINION: ONTARGET (ongoing telmisartan alone and in combination with ramipril global endpoint trial) demonstrated, that telmisartan confers cardiovascular protective effects similar to those of ramipril, but with a better tolerability. Moreover, recent investigations focused on the capability of telmisartan to modulate the peroxisome proliferator-activated receptor-gamma (PPAR-γ), an established target in the treatment of insulin resistance, diabetes and metabolic syndrome, whose activation is also correlated to anti-inflammatory and, finally, anti-atherosclerotic properties. Telmisartan shows peculiar features that go beyond blood pressure control. It presents promising and unique protective properties against target end-organ damage, potentially able to open a scenario of new therapeutic approaches to cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Destro et al. (2011) conducted a review in Hypertension. Telmisartan was evaluated. Telmisartan provides sustained blood pressure reduction and exhibits unique cardiovascular protective properties, including PPAR-γ modulation, that extend beyond its antihypertensive effects.
Synapse has enriched 10 related papers. Consider them for comparative context: